New sales executive will lead global commercial growth

HAIFA, Israel and MIAMI, Florida April 1 2020 – Insightec®, a commercial-stage global medical technology company, today announced addition to its executive management team with Chris Marrus joining in the position of Chief Commercial Officer.

“Insightec is strengthening the commercial leadership team to help drive the exponential growth of focused ultrasound,” says Maurice R. Ferré MD, Insightec’s CEO and Chairman of the Board of Directors. “Our transformative technology is attracting top talent to contribute to making focused ultrasound a standard of care.”

Chris Marrus brings extensive experience with disruptive technologies in the medical device industry. Marrus comes to Insightec from Stryker, where he has held the position of Vice President of Robotic Sales and Service for the last six years. Prior to Stryker, he held the position of Senior Vice President of Sales, Service and Training at Mako Surgical Corp, Vice President of Sales at Endogastric Solutions and Area Vice President at Intuitive Surgical. At Insightec, he will lead global commercialization of the company’s Incisionless Neurosurgery Platform.

###

About Insightec

Insightec is a global medical technology innovator transforming patient lives through incisionless brain surgery using focused ultrasound guided by MR imaging. The company’s award-winning Exablate Neuro device is FDA-approved to treat medication-refractory essential tremor and tremor-dominant Parkinson’s disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Shanghai and Tokyo.

Follow us on Facebook, LinkedIn and Twitter or visit www.insightec.com for more information.

Forward-looking Statements

This document contains forward-looking statements regarding, among other things, plans, expectations, and future events. In some cases, forward-looking statements can be identified by the following words: “may,” “can,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing,” or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec as of the date of the statement. All written or oral forward-looking statements attributable to Insightec are qualified by this caution. Insightec does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec’s expectations.

“Exablate,” and “Exablate Neuro,” as well as the “Insightec” logo, whether standing alone or in connection with the word “Insightec”, are protected trademarks of Insightec.

admin

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

A Better Tomorrow
Starts Here

Discover the transformative power of Incisionless Focused Ultrasound.

Start a Transformation
Start A Transformation
Font Resize